Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review

被引:46
作者
Mercadante, Sebastiano [1 ]
Bruera, Eduardo [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA
关键词
Methadone; cancer pain; opioids; adverse effects; strong opioids; opioids for moderate pain; LOW-DOSE METHADONE; ORAL METHADONE; MORPHINE; INITIATION; FENTANYL;
D O I
10.1016/j.jpainsymman.2017.10.017
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim. The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management. Methods. A systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain-and opioid-related adverse effects. Results. The initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (#10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time. Conclusion. Available data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs. (C) 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:998 / 1003
页数:6
相关论文
共 50 条
[41]   Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management [J].
Mercadante, Sebastiano ;
Porzio, Giampiero ;
Ferrera, Patrizia ;
Fulfaro, Fabio ;
Alelli, Federica ;
Verna, Lucilla ;
Villari, Patrizia ;
Ficorella, Corrado ;
Gebbia, Vittorio ;
Riina, Salvatore ;
Casuccio, Alessandra ;
Mangione, Salvatore .
EUROPEAN JOURNAL OF PAIN, 2008, 12 (08) :1040-1046
[42]   Methadone: An Effective, Safe Drug of First Choice for Pain Management in Frail Older Adults [J].
Gallagher, Romayne .
PAIN MEDICINE, 2009, 10 (02) :319-326
[43]   Intravenous methadone in the management of acute postoperative pain in a chronic cancer pain patient: A case report and review of the literature [J].
Le, Khang Duy Ricky ;
Hua, Jean .
CLINICAL CASE REPORTS, 2023, 11 (12)
[44]   A systematic review of oxycodone in the management of cancer pain [J].
King, Samuel James ;
Reid, Colette ;
Forbes, Karen ;
Hanks, Geoffrey .
PALLIATIVE MEDICINE, 2011, 25 (05) :454-470
[45]   Intravenous methadone in the management of chronic cancer pain - Safe and effective starting doses when substituting methadone for fentanyl [J].
Santiago-Palma, J ;
Khojainova, N ;
Kornick, C ;
Fischberg, DJ ;
Primavera, LH ;
Payne, R ;
Payne, R ;
Manfredi, P .
CANCER, 2001, 92 (07) :1919-1925
[46]   Review of Opioid Pharmacogenetics and Considerations for Pain Management [J].
Obeng, Aniwaa Owusu ;
Hamadeh, Issam ;
Smith, Michael .
PHARMACOTHERAPY, 2017, 37 (09) :1105-1121
[47]   Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain [J].
Benítez-Rosario, MA ;
Feria, M ;
Salinas-Martín, A ;
Martinez-Castillo, LP ;
Martin-Ortega, JJ .
CANCER, 2004, 101 (12) :2866-2873
[48]   Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain [J].
Moryl, N ;
Santiago-Palma, J ;
Kornick, C ;
Derby, S ;
Fischberg, D ;
Payne, R ;
Manfredi, PL .
PAIN, 2002, 96 (03) :325-328
[49]   Management of chronic neuropathic pain with methadone:: A review of 13 cases [J].
Altier, NG ;
Dion, D ;
Boulanger, A ;
Choinière, M .
CLINICAL JOURNAL OF PAIN, 2005, 21 (04) :364-369
[50]   Systematic Review on Barriers to Access Opioid Analgesics for Cancer Pain Management from the Health Worker Perspective [J].
Fleckner, Josephine ;
Pettus, Katherine ;
Vallath, Nandini ;
Pastrana, Tania .
JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY, 2023, 37 (04) :324-335